Simon Chivers

802 citations

20 papers · 533 indexed · h-index 11

Impact in

Oncology top 10%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Immunology
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 11
- CAR-T cell therapy research 8
- HER2/EGFR in Cancer Research 3
Toxicology 1

Co-authors: Francesca Zammarchi (12 shared papers)Patrick H. van Berkel (11 shared papers)Simon Corbett (7 shared papers)John A. Hartley (9 shared papers)Lauren Adams (6 shared papers)Karin Havenith (10 shared papers)Philip W. Howard (4 shared papers)David G. Williams (6 shared papers)
Journals: Cancer Research (5 papers)Blood (3 papers)Molecular Cancer Therapeutics (1 paper)Scientific Reports (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: United Kingdom Switzerland Germany

In The Last Decade

Simon Chivers

20 papers receiving 513 citations

Peers

Countries citing papers authored by Simon Chivers

Since Specialization

Citations

This map shows the geographic impact of Simon Chivers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Chivers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Chivers more than expected).

Fields of papers citing papers by Simon Chivers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Chivers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Chivers. The network helps show where Simon Chivers may publish in the future.

Co-authors

The 25 scholars most cited alongside Simon Chivers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Simon Chivers Line = papers co-authored together Simon Chivers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E.G. Havenith, Simon Chivers, François D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel	2018	118
2	Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine Scientific Reports ·John A. Hartley, Michael Flynn, John P. Bingham, Simon Corbett, Halla W. Reinert, Arnaud Tiberghien, Luke A. Masterson, Dyeison Antonow, Lauren Adams, Sajidah Chowdhury, David G. Williams, Shenlan Mao, Jay Harper, Carin E.G. Havenith, Francesca Zammarchi, Simon Chivers, Patrick H. van Berkel, Philip W. Howard	2018	85
3	Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia Journal of Clinical Investigation ·Lothar Seefried, Jasmin Baumann, Sarah Hemsley, Christine Hofmann, Erdmute Kunstmann, Beate Kiese, Yue Huang, Simon Chivers, Marie‐Anne Valentin, Babul Borah, Ronenn Roubenoff, U. Junker, Franz Jakob	2017	57
4	Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies Drug Discovery Today ·Kathryn Chapman, Simon Chivers, Dan Gliddon, David Mitchell, Sally Robinson, Tim Sangster, Susan Sparrow, Neil Spooner, Amanda Wilson	2014	56
5	CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity Journal for ImmunoTherapy of Cancer ·Francesca Zammarchi, Karin Havenith, François Bertelli, Balakumar Vijayakrishnan, Simon Chivers, Patrick H. van Berkel	2020	55
6	Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies Journal of Pharmacological and Toxicological Methods ·Brian D. Guth, A S Bass, Richard J. Briscoe, Simon Chivers, Michael Markert, Peter K. S. Siegl, Jean‐Pierre Valentin	2009	41
7	Placental Transfer of Fc‐Containing Biopharmaceuticals across Species, an Industry Survey Analysis Birth Defects Research Part B Developmental and Reproductive Toxicology ·Christopher Bowman, William J. Breslin, Anu Connor, Pauline L. Martin, Graeme J. Moffat, Lakshmi Sivaraman, M.B. Tornesi, Simon Chivers	2013	32
8	Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights Regulatory Toxicology and Pharmacology ·Guenter Blaich, Andreas Baumann, Sven Kronenberg, Lolke de Haan, Peter Ulrich, W. Richter, Jay Tibbitts, Simon Chivers, Edit Tarcsa, Robert Granville Caldwell, Flavio Crameri	2016	15
9	ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers European Journal of Cancer ·Francesca Zammarchi, Simon Chivers, David G. Williams, Lauren Adams, Maria Mellinas‐Gomez, Peter Tyrer, Simon Corbett, François D’Hooge, Sandamali Dissanayake, Simone Sims, Karin Havenith, Philip W. Howard, J.A. Hartley, Patrick H. van Berkel	2016	14
10	hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies. Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Maria Mellinas‐Gomez, Peter Tyrer, Sandamali Dissanayake, Simone Sims, Karin Havenith, Simon Chivers, David G Willimas, Philip W. Howard, John A. Hartley, Patrick van Berkel	2016	12
11	Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model? Calcified Tissue International ·László B. Tankó, Jörg Goldhahn, Aurore Varela, Elisabeth Lesage, Susan Y. Smith, Andrew Pilling, Simon Chivers	2016	11
12	Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease Toxicological Sciences ·David A. Rider, Simon Chivers, Julia Aretz, Mona Eisermann, Kathrin Löffler, Judith Hauptmann, Eliot Morrison, G. Campion	2022	9
13	Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies Blood ·Francesca Zammarchi, David G. Williams, Lauren Adams, Karin Havenith, Simon Chivers, François D’Hooge, Philip W. Howard, John A. Hartley, Patrick H. van Berkel	2015	8
14	ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies Molecular Cancer Therapeutics ·Francesca Zammarchi, Karin Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, François Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel	2024	6
15	Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors Cancer Research ·Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul W. Hogg, Charlie Britten, Sandamali Dissanayake, Peter Tyrer, François Bertelli, Ian Hutchinson, Luke A. Masterson, Phil W. Howard, John A. Hartley, Patrick H. van Berkel	2018	4
16	Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors Cancer Research ·Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul W. Hogg, Charlie Britten, Sandamali Dissanayake, Peter Tyrer, François Bertelli, Ian Hutchinson, Luke A. Masterson, Phil W. Howard, John A. Hartley, Patrick H. van Berkel	2018	4
17	Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies Cancer Research ·Francesca Zammarchi, François Bertelli, Karin Havenith, Ian Kirby, Simon Chivers, Patrick H. van Berkel	2019	3
18	Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies Cancer Research ·Francesca Zammarchi, Simon Corbett, Karin Havenith, Narinder Janghra, Konstantinos Kiakos, Teresa Marafioti, David G. Williams, Simon Chivers, Phil W. Howard, John A. Hartley, Patrick H. van Berkel	2017	1
19	LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47). Journal of Clinical Oncology ·Jonny Finlay, Antoine Yver, Simon Chivers, David W. Grainger	2022	1
20	Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers Cancer Research ·Francesca Zammarchi, Simon Chivers, Karin Havenith, David G. Williams, Lauren Adams, Maria Mellinas‐Gomez, Simon Corbett, Peter Tyrer, François D’Hooge, Song Cho, Nazzareno Dimasi, Mary Jane Hinrichs, Phil W. Howard, John A. Hartley, Patrick H. van Berkel	2017	1

About Simon Chivers

Simon Chivers is a scholar working on Oncology, Toxicology, Neurology, Immunology and Orthopedics and Sports Medicine, having authored 20 papers that have together received 533 indexed citations. Recurring topics across this work include CAR-T cell therapy research (8 papers), Cancer therapeutics and mechanisms (5 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers), Neuroblastoma Research and Treatments (4 papers), HER2/EGFR in Cancer Research (3 papers), Bone health and osteoporosis research (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and Lymphoma Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (286 citations), Immunology (130 citations), Small Animals (45 citations), Radiology, Nuclear Medicine and Imaging (137 citations) and Pathology and Forensic Medicine (99 citations). Simon Chivers has collaborated with scholars based in United Kingdom, Switzerland and Germany. Frequent co-authors include Francesca Zammarchi, Patrick H. van Berkel, Simon Corbett, John A. Hartley, Lauren Adams, Karin Havenith, Philip W. Howard, David G. Williams, Carin E.G. Havenith and Arnaud Tiberghien. Their work appears in journals such as Cancer Research, Blood, Molecular Cancer Therapeutics, Scientific Reports and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact